News Search Results

Displaying Results 51-75 of 817 "cns"

Oct 03, 2025, 22:48 ET Clearmind Biomedical Signs Exclusive U.S. Distribution Agreement with Sutter Medical Technologies USA and launches the Neuroblade System at Congress of Neurological Surgeons (CNS) Los Angeles, CA.

workflow, precision and enhance patient outcomes." The Neuroblade will be featured at the Congress of Neurological Surgeons (CNS) Annual Meeting, October 11-15th, 2025 at Booth #350. About Clearmind Biomedical

More news about: Clearmind Biomedical Inc.


Oct 03, 2025, 09:00 ET Mitsubishi Tanabe Pharma America to Present New Data on Investigational ND0612 at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at

More news about: Mitsubishi Tanabe Pharma America


Oct 03, 2025, 08:30 ET Koh Young to Showcase Next Gen Navigated Neurosurgical Robot at CNS Innovation Symposium

announced it will present its FDA-cleared navigated neurosurgical positioning robot, Geniant® Cranial at the upcoming Congress of Neurological Surgeons (CNS) "Special Symposium: Transforming Neurosurgery through Technology," taking place on October 12, 2025.

More news about: Koh Young Technology


Oct 02, 2025, 11:36 ET ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease

platform offers exceptional flexibility, paving the way for large molecule therapies—including those previously unable to reach therapeutic levels in the CNS—to become viable options for treatment of neurological conditions, brain cancers, and gene therapies. Market

More news about: ExQor Technologies Inc


Oct 02, 2025, 08:08 ET Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775

3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus–treated patients, including 1 fatal cerebral hemorrhage.

More news about: Eisai Inc.


Oct 02, 2025, 08:00 ET Aminex Therapeutics Announces FDA Orphan Drug Designation Granted to AMXT 1501 in Combination with DFMO for the Treatment of Neuroblastoma

Escalation Study Using Eflornithine (DFMO) and AMXT 1501 Followed by a Randomized Controlled Trial of DFMO with or without AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas"

More news about: Aminex Therapeutics, Inc.


Oct 02, 2025, 06:36 ET ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease

platform offers exceptional flexibility, paving the way for large molecule therapies—including those previously unable to reach therapeutic levels in the CNS—to become viable options for treatment of neurological conditions, brain cancers, and gene therapies. Market

More news about: ExQor Technologies Inc


Oct 01, 2025, 10:00 ET Surgical Theater Surpasses 50,000 XR Utilizations

The announcement comes as Surgical Theater prepares to showcase new capabilities at CNS and NASS congresses this fall, where surgeons and hospital leaders will experience firsthand how XR transforms planning and intraoperative execution.

More news about: SURGICAL THEATER


Oct 01, 2025, 09:21 ET Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG

standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the

More news about: Kazia Therapeutics Limited


Oct 01, 2025, 08:53 ET Mercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein Cargo to the Brain

brain cells." The blood-brain barrier (BBB) forms a protective shield around the brain, insulating the central nervous system (CNS) from pathogens, toxins, hormones, and other substances in the blood that could disrupt brain function. This role is essential for survival but makes

More news about: Mercury Bio Inc.


Oct 01, 2025, 00:58 ET LG CNS Leverages Manufacturing AX Tech to Target the Middle East Oil Market

Oct. 1, 2025 /PRNewswire/ -- LG CNS, a leading AX (AI Transformation) company in Korea, is set to expand into Middle Eastern markets with its advanced manufacturing-focused AX technologies. From September 30 to October 2, LG CNS participated in the International Downstream

More news about: LG CNS


Sep 30, 2025, 07:00 ET NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting

Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced clinical-stage

More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.


Sep 29, 2025, 17:52 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)

https://www.cohenandsteers.comSymbol: (NYSE: CNS)

More news about: Cohen & Steers, Inc.


Sep 29, 2025, 17:51 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)

https://www.cohenandsteers.comSymbol: (NYSE: CNS)

More news about: Cohen & Steers, Inc.


Sep 29, 2025, 17:39 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)

https://www.cohenandsteers.com/Symbol: (NYSE: CNS)

More news about: Cohen & Steers, Inc.


Sep 29, 2025, 17:35 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)

https://www.cohenandsteers.comSymbol: (NYSE: CNS)

More news about: Cohen & Steers, Inc.


Sep 29, 2025, 17:28 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)

https://www.cohenandsteers.comSymbol: (NYSE: CNS)

More news about: Cohen & Steers, Inc.


Sep 29, 2025, 10:00 ET iQure Pharma Secures US Patent for iQ-007, a First-in-Class Small Molecule Restoring Glutamate Balance in CNS Disorders

2025 /PRNewswire/ -- iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a US patent for iQure's clinical-stage asset iQ-007.

More news about: iQure Pharma Inc.


Sep 25, 2025, 07:37 ET Precision Medicine Protocol Shows Dual Benefits: Improved Cognition and Reduced Depression

have demonstrated that ReCODE can improve cognition in patients with early Alzheimer's and mild cognitive impairment. About CNS Vital Signs CNS Vital Signs is a leading provider of computerized neurocognitive assessments, offering clinicians efficient

More news about: Apollo Health


Sep 25, 2025, 07:00 ET Corero Network Security Enters Singapore Market Through Partnership with ONESECURE Asia

Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced its strategic partnership

More news about: Corero Network Security


Sep 25, 2025, 06:30 ET AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer

NeurimmuneNeurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. With its Reverse Translational

More news about: AL-S Pharma AG


Sep 25, 2025, 06:30 ET Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

central nervous system (CNS), including decreased number of pathogenic T helper cells producing interleukin-17A (IL-17A), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon gamma (IFNγ). Prophylactic dosing also increased expression of Nurr1 target genes in the CNS, elevated plasma brain-derived

More news about: Immunic, Inc.


Sep 24, 2025, 19:00 ET Corero Network Security Masuk Pasar Singapura Melalui Kemitraan Dengan ONESECURE Asia

Corero Network Security (AIM: CNS) (OTCQX: DDOSF) adalah perusahaan terdepan yang diakui di bidang perlindungan DDoS dan yang terbaik dalam hal ketersediaan layanan adaptif di waktu nyata.

More news about: Corero Network Security


Sep 24, 2025, 10:52 ET Cognision and SOMNOmedics Forge Strategic Partnership to Advance Sleep Biomarkers in Pharmaceutical Clinical Trials

gold-standard electroencephalography (EEG) and event-related potential (ERP) biomarkers. "Sleep endpoints are becoming increasingly important in CNS drug development, from neurodegeneration and neuropsychiatric disorders to pain and emerging psychedelic therapies," said Dr. Igor

More news about: Cognision


Sep 24, 2025, 10:00 ET FYR Closes $8 Million Financing to Advance Blood-Based Biomarkers Across Oncology and Neuroscience

Two Bear Capital. "Their platform is scaling across solid tumors and also unlocks CNS applications where clean, noninvasive signals are notoriously hard to capture. We're excited to support the natural expansion of their platform into

More news about: FYR Diagnostics


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.